Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Nifty is in a long term uptrend. Intermediate target is 24035. Buy on Dips: HDFC Sec



Monthly Technical Outlook
03 Feb 2024

A Chart Book On Benchmark, Sectors, Global Market and Inter Market Analysis

Nifty remains in a long term uptrend. Our intermediate target is at 24035 for the coming months.

Mid Cap and Small Cap indices remain in intermediate uptrend.

Large caps At Better Risk Reward Ratio Against Midcap/ Small caps

PSU Banks Have Started Gaining Momentum Over Private Bank

Global Market Update: Nikkei trend remains up. Buy the dips. S&P 500 has witnessed a channel breakout.

Click here to download HSL Retail Research Monthly Technical Report 03 Feb 2024

investments

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 486 other subscribers

RSS Stocks Talk Forum

  • Skipper has Target Price of ₹650 (44% upside)
    Skipper has presence across the T&D ecosystem & is poised for a powerful performance. It stands to benefit immensely from domestic & export order intake tailwinds. It is doubling tower capacity & is only backward-integrated player in India. TP ₹650 (44%) Download research report ... Skipper has Target Price of ₹650 (44% upside)
  • Ashish Kacholia has invested ₹60 Cr in 2.52% of Jyoti Structures
    Ashish Kacholia has invested ₹60 Cr in 2.52% of Jyoti Structures. M-Cap is ₹2400 Cr. Co was rescued from insolvency by Sharad Sanghi of Netmagic. Co is play on infra & power sector as it has expertise in turnkey EPC solutions for electricity transmission, distribution (T&D) etc
  • Jubilant Pharmova has a diversified & unique business model with new growth drivers. 30% upside
    Jubilant Pharmova has a diversified & unique business model with new growth drivers & multiple triggers. It has growth visibility & revenue potential of $350 Mn. Co is embarking on a new earnings cycle. PAT has potential to grow 4x. TP ₹1450 (30%) Download research report... Jubilant Pharmova has a diversified & unique business model […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!